crlf3 Antibody

What is CRLF3 and why is it important in research?

CRLF3 (Cytokine receptor-like factor 3) is an evolutionary conserved orphan cytokine receptor that has been implicated in various biological processes and diseases. It plays a crucial role in neuroprotection, particularly upon activation with the natural erythropoietin (Epo) splice variant EV-3 . Additionally, CRLF3 is important in hematopoiesis, specifically in platelet production, as CRLF3 deficiency causes an isolated and sustained reduction in platelet count without affecting other blood cell lineages . The protein is expressed in multiple tissues including brain, liver, spleen, pancreas, and adult kidney, making it relevant for research across several physiological systems . Given its involvement in neuronal protection, platelet formation, and potential link to various diseases including neurofibromatosis type I and cancer, CRLF3 has become an important target for investigation in both basic and translational research.

What applications are CRLF3 antibodies validated for?

CRLF3 antibodies are primarily validated for Western blotting (WB) applications, as indicated by multiple commercial antibodies . This allows researchers to detect endogenous levels of CRLF3 protein in various tissue and cell lysates. Some antibodies may also be validated for ELISA applications . When selecting a CRLF3 antibody, researchers should verify that it has been tested for reactivity with their species of interest, as different antibodies may show different reactivity profiles. For instance, some antibodies are reactive with both human and mouse samples , which is valuable for comparative studies across species. Validation data typically includes Western blot images showing the expected band at approximately 48-55 kDa, corresponding to the molecular weight of CRLF3 .

How should CRLF3 antibodies be validated before use in critical experiments?

For rigorous validation of CRLF3 antibodies before use in critical experiments, researchers should implement a multi-step approach:

• Knockout/knockdown controls: Generate CRLF3 knockout or knockdown samples as negative controls. As demonstrated in the literature, CRLF3 knockout iPSC lines and derived neurons show absence of CRLF3 immunoreactivity, providing strong validation of antibody specificity .

• Western blot analysis: Verify that the antibody detects a single band at the expected molecular weight (~48-55 kDa) in positive control samples while showing no signal in knockout/knockdown samples .

• Cross-reactivity testing: If working across multiple species, confirm reactivity with the intended species. Some CRLF3 antibodies react with both human and mouse samples, which should be experimentally verified .

• Immunocytochemistry validation: For imaging applications, compare staining patterns between wildtype and knockout cells. Specific CRLF3 antibodies should show characteristic dot-like patterns in wild-type cells but not in CRLF3 knockout cells .

• Reproducibility assessment: Test multiple antibody lots if possible and ensure consistent results across independent experiments.

Proper validation is particularly important for CRLF3 research, as the protein's expression can vary significantly across different cell types and physiological conditions.

What are the optimal conditions for Western blotting using CRLF3 antibodies?

For optimal Western blot detection of CRLF3 protein, researchers should consider the following protocol recommendations:

• Sample preparation:

  • For cellular samples, use a lysis buffer containing protease inhibitors

  • Ensure equal protein loading (20-50 μg total protein per lane)

  • Include positive controls (tissues known to express CRLF3, e.g., brain, liver, or spleen)

  • Include negative controls (CRLF3 knockout samples if available)

• Antibody dilution:

  • Typically use a dilution range of 1:500-1:2000 for primary antibody incubation

  • Optimize based on antibody concentration (typically 1 mg/ml for commercial antibodies)

• Detection considerations:

  • CRLF3 and α-Tubulin have similar molecular weights (~55 kDa), which may complicate analysis if using α-Tubulin as a loading control

  • Use alternative loading controls or differential labeling strategies

• Storage and handling:

  • Store antibodies according to manufacturer recommendations, typically at -20°C

  • Avoid repeated freeze-thaw cycles that may degrade antibody quality

When analyzing results, be aware that CRLF3 expression levels may change in response to experimental treatments. For example, rotenone exposure has been shown to increase CRLF3 levels in iPSC-derived neurons compared to untreated controls .

How can researchers assess changes in CRLF3 protein levels under different experimental conditions?

To accurately assess changes in CRLF3 protein levels under different experimental conditions, researchers should employ quantitative approaches:

• Western blot quantification:

  • Run samples from control and treated conditions simultaneously on the same gel

  • Use appropriate loading controls (considering potential molecular weight overlap with α-Tubulin)

  • Perform densitometric analysis to quantify relative band intensities

  • Calculate fold changes compared to control conditions

• Experimental design considerations:

  • Include time-course experiments to capture dynamic changes in CRLF3 expression

  • Analyze both total protein levels and potential subcellular redistribution

  • Consider parallel analysis of mRNA expression to determine if changes occur at transcriptional or post-transcriptional levels

• Statistical analysis:

  • Conduct multiple independent experiments (n≥3)

  • Report data as mean ± standard deviation or standard error

  • Perform appropriate statistical tests to determine significance of observed changes

Research has shown that experimental manipulations can significantly alter CRLF3 expression. For example, exposure to rotenone increased CRLF3 levels in iPSC-derived neurons by 2.1 ± 0.7 fold compared to untreated controls, and this increase was partially reduced by co-treatment with EV-3 .

How can CRLF3 antibodies be utilized to study CRLF3's interactions with other proteins?

CRLF3 antibodies can be effectively employed to study protein-protein interactions through several advanced methodologies:

• Co-immunoprecipitation (Co-IP):

  • Use CRLF3 antibodies to pull down CRLF3 and its binding partners

  • Analyze precipitated complexes by Western blot or mass spectrometry

  • Include appropriate controls (IgG control, knockout cell lysates)

  • Consider crosslinking approaches for transient interactions

• Proximity ligation assay (PLA):

  • Combine CRLF3 antibody with antibodies against suspected interaction partners

  • Visualize protein proximity (<40 nm) in situ through fluorescent signals

  • Quantify interaction events per cell under different conditions

• Tagged protein approaches:

  • As demonstrated in the literature, TAP-tagged CRLF3 can be used in iPSC-derived megakaryocytes for pull-down experiments

  • Anti-FLAG immunoprecipitation followed by mass spectrometry identified STK38 as a candidate interacting protein

  • Confirm interactions through reverse pull-downs and Western blotting

• Protein complex analysis:

  • Fractionate cellular components to identify CRLF3-enriched compartments

  • Western blot analysis has shown enrichment of CRLF3 in cytoskeletal protein fractions, particularly with α-tubulin

By applying these approaches, researchers have identified important CRLF3 interactions, such as its association with STK38, a member of the NDR kinase group known to interact with MOB1 in the Hippo pathway .

What are the key considerations when studying CRLF3 in neuroprotection models?

When investigating CRLF3's role in neuroprotection, researchers should address several critical experimental considerations:

• Cell model selection:

  • iPSC-derived neurons provide a human-relevant model for neuroprotection studies

  • Compare wild-type cells with CRLF3 knockout cells to establish causality

  • Consider the differentiation efficiency of neuronal cultures, as lower efficiency may confound results

• Apoptosis induction:

  • Rotenone challenge (0.1 μM) has been successfully used to induce apoptosis in CRLF3 studies

  • Titrate toxin concentrations to achieve consistent apoptotic responses

  • Include appropriate positive and negative controls

• Neuroprotective interventions:

  • The natural Epo splice variant EV-3 (8 ng/ml) can be used to activate CRLF3-mediated neuroprotection

  • Compare responses between wild-type and CRLF3 knockout neurons to confirm receptor specificity

  • Consider temporal aspects (pre-treatment vs. co-treatment vs. post-treatment)

• Readout selection:

  • Apoptosis markers (e.g., cleaved caspase-3, TUNEL)

  • Gene expression analysis of pro- and anti-apoptotic genes

  • Morphological assessment (soma size, dendrite number)

  • Functional measures (electrophysiology, calcium imaging)

• Mechanistic investigations:

  • Analyze differential expression of pro- and anti-apoptotic genes in response to treatments

  • Examine CRLF3 protein levels and localization under apoptogenic and rescue conditions

These considerations will help researchers design rigorous experiments to elucidate CRLF3's neuroprotective mechanisms and potentially identify therapeutic targets for neurological disorders.

How can CRLF3 expression and function be studied in platelet production models?

To investigate CRLF3's role in thrombopoiesis (platelet production), researchers should implement specialized approaches:

• Model systems:

  • In vivo: CRLF3 knockout mouse models show isolated 25-48% reduction in platelet count

  • Ex vivo: Bone marrow transplantation experiments to determine the hematopoietic-intrinsic nature of phenotypes

  • In vitro: iPSC-derived megakaryocytes for mechanistic studies

• Phenotypic analysis:

  • Complete blood counts to assess platelet parameters

  • Platelet morphology and function assays

  • Megakaryocyte maturation and proplatelet formation assessment

  • Preplatelet maturation and fission analysis

• Mechanistic investigations:

  • Study microtubule dynamics and stability in wild-type vs. CRLF3-deficient preplatelets

  • Analyze post-translational modifications of tubulin (particularly glutamylation)

  • Investigate interactions between CRLF3 and Hippo pathway components (STK38, MOB1)

• Genetic approaches:

  • CRLF3-tagged constructs to track protein localization during megakaryocyte differentiation and proplatelet formation

  • Study redistribution patterns from cytoplasmic to membrane localization during proplatelet formation

  • Human genetic association studies can identify variants in CRLF3 associated with platelet parameters

• Therapeutic potential assessment:

  • Evaluate CRLF3 as a target for thrombocythemia using disease models such as JAK2 V617F essential thrombocythemia

  • Develop and test CRLF3 inhibitors for lineage-specific normalization of platelet counts

Research has demonstrated that CRLF3 plays a key role in the final stage of platelet genesis and represents a potential therapeutic target for thrombocythemia .

What are common challenges when working with CRLF3 antibodies and how can they be addressed?

When working with CRLF3 antibodies, researchers may encounter several technical challenges:

• Cross-reactivity issues:

  • Challenge: Non-specific binding to proteins with similar structural domains, as CRLF3 contains a fibronectin type-III domain

  • Solution: Validate antibody specificity using CRLF3 knockout controls; use antibodies raised against unique peptide regions (e.g., AA range 270-350 in human CRLF3)

• Signal detection limitations:

  • Challenge: Low endogenous expression levels in certain cell types

  • Solution: Optimize protein loading (≥20 μg), increase antibody concentration, or use enhanced chemiluminescence detection systems

• Molecular weight overlap with common loading controls:

  • Challenge: CRLF3 and α-Tubulin both have molecular weights of approximately 55 kDa

  • Solution: Use alternative loading controls or differentially labeled secondary antibodies for simultaneous detection

• Tissue/cell type variability:

  • Challenge: CRLF3 expression varies across tissues and developmental stages

  • Solution: Include positive control samples from tissues known to express CRLF3 (e.g., brain, liver, spleen); consider tissue-specific optimization

• Antibody stability issues:

  • Challenge: Loss of antibody activity with repeated freeze-thaw cycles

  • Solution: Aliquot antibodies upon receipt; store according to manufacturer recommendations (typically -20°C in glycerol-containing buffer)

• Inconsistent immunostaining patterns:

  • Challenge: Variable localization patterns depending on cell type and state

  • Solution: Characterize expected localization patterns in control samples; consider cell state-specific controls (e.g., differentiating vs. mature cells)

Addressing these challenges through systematic optimization and appropriate controls will enhance the reliability and reproducibility of CRLF3 antibody-based experiments.

How can researchers distinguish between specific and non-specific signals when using CRLF3 antibodies?

Distinguishing between specific and non-specific signals is critical for accurate interpretation of CRLF3 antibody experiments:

• Essential controls:

  • Negative genetic controls: Use CRLF3 knockout or knockdown samples to identify non-specific signals

  • Isotype controls: Include matched isotype antibodies to identify Fc receptor-mediated binding

  • Peptide competition: Pre-incubate antibody with immunizing peptide to block specific binding

  • Secondary-only controls: Omit primary antibody to identify non-specific secondary antibody binding

• Signal validation approaches:

  • Multiple antibodies: Use antibodies targeting different epitopes of CRLF3

  • Multiple detection methods: Compare results from different techniques (Western blot, immunofluorescence)

  • Quantitative assessment: Compare signal-to-noise ratios under different conditions

• Technical considerations:

  • Blocking optimization: Test different blocking agents (BSA, normal serum, commercial blockers)

  • Antibody dilution titration: Determine optimal concentration that maximizes specific signal while minimizing background

  • Washing stringency: Adjust salt concentration and detergent levels in wash buffers

• Pattern recognition:

  • Expected localization: CRLF3 shows specific patterns (dot-like in neuronal cell bodies and axons; cytoplasmic or membrane-associated in megakaryocytes)

  • Expected molecular weight: Specific signal at 48-55 kDa in Western blots

  • Treatment-responsive changes: Specific signals should change in response to relevant treatments (e.g., increased with rotenone exposure)

Implementing these approaches will help researchers confidently identify specific CRLF3 signals and avoid misinterpretation of experimental results.

What emerging techniques might enhance CRLF3 antibody-based research?

Emerging technologies are poised to advance CRLF3 antibody-based research in several key directions:

• Single-cell protein analysis:

  • Mass cytometry (CyTOF) with CRLF3 antibodies could reveal cell-specific expression patterns

  • Multiplex imaging approaches (CODEX, Imaging Mass Cytometry) to analyze CRLF3 in tissue context

  • Single-cell Western blotting to quantify CRLF3 protein heterogeneity across individual cells

• Advanced microscopy applications:

  • Super-resolution microscopy (STORM, PALM) to resolve subcellular CRLF3 localization beyond diffraction limit

  • Live-cell imaging with tagged nanobodies to track CRLF3 dynamics in real-time

  • Correlative light and electron microscopy (CLEM) to link CRLF3 immunolabeling with ultrastructural features

• Protein interaction mapping:

  • Proximity labeling methods (BioID, APEX) combined with CRLF3 antibodies to identify context-specific interactomes

  • FRET/FLIM-based approaches to study dynamic CRLF3 protein interactions

  • Spatial proteomics to map CRLF3 interactions within specific subcellular compartments

• Functional antibody applications:

  • Development of function-blocking CRLF3 antibodies to modulate receptor activity

  • Antibody-drug conjugates targeting CRLF3 for potential therapeutic applications

  • Intrabodies to manipulate CRLF3 function in specific cellular compartments

• Quantitative proteomics integration:

  • Targeted mass spectrometry approaches (PRM, MRM) for absolute quantification of CRLF3 protein

  • Post-translational modification mapping using specialized antibodies

  • Integrative multi-omics approaches linking CRLF3 protein dynamics with transcriptomics and metabolomics

These emerging techniques promise to provide unprecedented insights into CRLF3 biology and may facilitate translation of basic research findings into clinical applications.

How might genetic association findings guide CRLF3 antibody research priorities?

Genetic association findings provide important directions for prioritizing CRLF3 antibody research:

• Variant-specific studies:

  • Genetic variants in the CRLF3 locus have been significantly associated with platelet distribution width

  • Research priority: Develop antibodies that can detect variant-specific CRLF3 proteins or post-translational modifications

  • Investigate how variants affect protein expression, localization, and function using comparative antibody-based approaches

• Tissue-specific investigations:

  • Variants in STK38 (a CRLF3 interacting protein) associate with mean platelet volume, while MOB1A variants associate with platelet count

  • Research priority: Use co-immunoprecipitation with CRLF3 antibodies to study how these genetic variants affect protein interaction networks

  • Analyze tissue-specific expression patterns in individuals with different genetic backgrounds

• Disease mechanism elucidation:

  • CRLF3 has been implicated in multiple diseases including neurofibromatosis type I, cutaneous Leishmaniasis, and cancer

  • Research priority: Develop antibody panels to analyze CRLF3 pathway components in patient-derived samples

  • Correlate genetic findings with protein expression patterns in relevant disease tissues

• Therapeutic target validation:

  • CRLF3 deficiency normalizes platelet count in a mouse model of JAK2 V617F essential thrombocythemia

  • Research priority: Develop antibodies suitable for immunohistochemistry to assess CRLF3 expression in patient samples

  • Use antibody-based screening approaches to identify small molecules that modulate CRLF3 function

• Functional genomics integration:

  • Combine CRISPR-based genetic manipulation with antibody-based protein analysis

  • Research priority: Develop antibodies that can detect specific functional domains of CRLF3 to correlate genetic variants with functional consequences

  • Create isogenic cell lines with disease-associated variants for comparative antibody-based studies

By aligning antibody-based research with genetic findings, investigators can more effectively translate genomic discoveries into mechanistic insights and potential therapeutic approaches.